Sanofi Highlights MS Asset After Solid Q4

BTK Inhibitor Entering Phase III Soon

 
• By Sten Stovall
  
Sanofi_Berlin
Sanofi is refocusing its business model and narrowing therapeutic priorities • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business